79. Homozygous familial hypercholesterolemia Clinical trials / Disease details
Clinical trials : 145 / Drugs : 114 - (DrugBank : 26) / Drug target genes : 8 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-001446-25-IT (EUCTR) | 02/10/2017 | 06/05/2021 | This is a study to investigate if gene therapy is safe in people with homozygous familial hypercholesterolemia (also called HoFH). | AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) | Adults with homozygous familial hypercholesterolemia;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Product Name: AAV8.TBG.hLDLR Product Code: AAV8.TBG.hLDLR Product Name: prednisone Product Code: prednisone | REGENXBIO Inc. | NULL | Not Recruiting | Female: yes Male: yes | 12 | Phase 1;Phase 2 | United States;Canada;Netherlands;Italy |